Madopar (Benserazide Hydrochloride, Levodopa)

Madopar is used in the management of Parkinsonian disorders, targeting dopaminergic pathways to improve motor function.

• Parkinson's disease: reduces rigidity, bradykinesia and tremor, enhancing daily activity performance.
• Parkinsonian syndrome: alleviates motor deficits caused by idiopathic or secondary Parkinsonism.
• Drug‑induced Parkinsonism: mitigates symptoms when antipsychotic‑induced dopamine blockade is present.

• Levodopa is a precursor that crosses the blood‑brain barrier and is decarboxylated to dopamine within central neurons. Benserazide, a peripheral dopa decarboxylase inhibitor, prevents conversion of levodopa outside the brain, thereby increasing the amount of levodopa that reaches the central nervous system and enhancing dopaminergic neurotransmission.

Madopar may cause a range of adverse reactions, most of which are dose‑related and reversible upon adjustment.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Orthostatic hypotension: dizziness upon standing.
• Dyskinesia: involuntary movements, especially at higher doses.
• Insomnia: difficulty initiating or maintaining sleep.
• Dry mouth: reduced salivation.
• Mood changes: anxiety or depression.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity.
• Severe cardiac arrhythmias: rare but potentially fatal.
• Hallucinations: visual or auditory disturbances.
• Severe orthostatic hypotension leading to falls.

When prescribing Madopar, clinicians should consider patient‑specific factors and monitor for adverse events.

• Renal impairment: adjust dose as clearance may be reduced.
• Hepatic dysfunction: use caution due to altered metabolism.
• Concomitant MAO‑B inhibitors: avoid combined use to reduce risk of hypertensive crisis.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Elderly patients: start with low dose and titrate slowly to minimize dyskinesia.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Madopar interacts with several drug classes that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics with strong D2 antagonism (e.g., haloperidol): may negate therapeutic effect.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance orthostatic hypotension.
• Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours.
• SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.